Semaglutide FLOW Kidney and Heart Findings: What Patients Should Know 6th June 20266th June 2026 by Living Diabetes Editorial A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
Tirzepatide and Heart Outcomes: What SURPASS-CVOT Shows 6th June 202626th March 2026 by Living Diabetes Editorial Team SURPASS-CVOT compared tirzepatide with dulaglutide in type 2 diabetes and ASCVD. Learn what the result does and does not prove.
